Giant Biogene Pre-IPO - The Negatives - Co-Founders Have Already Cashed in US$1bn+
Giant Biogene (GB) aims to raise around US$500m in its Hong Kong IPO. It is the largest recombinant collagen based products maker in China.
386 Views
Pinduoduo: Community Group Buying Is Facing Multiple Challenges
With QoQ revenue growth at a standstill and sales and marketing cost cutting almost fully exhausted, we think the current consensus expectations...
282 Views
Smartkarma Originals
Dealshare Tearsheet - Social Commerce For the Masses
India Unicorn Series: We profile India's social commerce platform for the masses "Dealshare". The model and execution are interesting, with...
431 Views
Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction
Legend Biotech Corp (LEGN US), a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is planning to raise up to US$250m in...
301 Views
Beneunder Pre-IPO - The Positives - Basking in the Sun
Beneunder Limited aims to raise around US$500m in its Hong Kong IPO. Sales have grown 6x over FY19-21. In this note, we talk about the positive...
325 Views